500 related articles for article (PubMed ID: 29801580)
1. Cytochrome P450 in Pharmacogenetics: An Update.
Tornio A; Backman JT
Adv Pharmacol; 2018; 83():3-32. PubMed ID: 29801580
[TBL] [Abstract][Full Text] [Related]
2. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation.
Zanger UM; Turpeinen M; Klein K; Schwab M
Anal Bioanal Chem; 2008 Nov; 392(6):1093-108. PubMed ID: 18695978
[TBL] [Abstract][Full Text] [Related]
3. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.
van Schaik RH
Invest New Drugs; 2005 Dec; 23(6):513-22. PubMed ID: 16267627
[TBL] [Abstract][Full Text] [Related]
4. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
Pharmacogenet Genomics; 2008 Jun; 18(6):515-23. PubMed ID: 18496131
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacogenetics and potential application in personalized medicine.
Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
[TBL] [Abstract][Full Text] [Related]
6. In vitro inhibitory mechanisms and molecular docking of 1'-S-1'-acetoxychavicol acetate on human cytochrome P450 enzymes.
Haque AKMM; Leong KH; Lo YL; Awang K; Nagoor NH
Phytomedicine; 2017 Jul; 31():1-9. PubMed ID: 28606510
[TBL] [Abstract][Full Text] [Related]
7. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
Zhou SF; Liu JP; Chowbay B
Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
[TBL] [Abstract][Full Text] [Related]
8. Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles.
Chamboko CR; Veldman W; Tata RB; Schoeberl B; Tastan Bishop Ö
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834793
[TBL] [Abstract][Full Text] [Related]
9. Effects of Khat (Catha edulis) use on catalytic activities of major drug-metabolizing cytochrome P450 enzymes and implication of pharmacogenetic variations.
Bedada W; de Andrés F; Engidawork E; Hussein J; LLerena A; Aklillu E
Sci Rep; 2018 Aug; 8(1):12726. PubMed ID: 30143732
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of the major polymorphic metabolizing enzymes.
Daly AK
Fundam Clin Pharmacol; 2003 Feb; 17(1):27-41. PubMed ID: 12588628
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome p450 part 2: what nurses need to know about the cytochrome p450 family systems.
Krau SD
Nurs Clin North Am; 2013 Dec; 48(4):681-96. PubMed ID: 24295195
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450-mediated metabolism of triclosan attenuates its cytotoxicity in hepatic cells.
Wu Y; Chitranshi P; Loukotková L; Gamboa da Costa G; Beland FA; Zhang J; Fang JL
Arch Toxicol; 2017 Jun; 91(6):2405-2423. PubMed ID: 27896399
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Herb-Drug Interaction of Synacinn™ and Individual Biomarker through Cytochrome 450 Inhibition Assay.
Ab Rahman NS; Abd Majid FA; Abd Wahid ME; Zainudin AN; Zainol SN; Ismail HF; Wong TS; Tiwari NK; Giri S; Bhargava V
Drug Metab Lett; 2018; 12(1):62-67. PubMed ID: 29542427
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics.
Cacabelos R; Llovo R; Fraile C; Fernández-Novoa L
Curr Alzheimer Res; 2007 Sep; 4(4):479-500. PubMed ID: 17908053
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.
Sim SC; Kacevska M; Ingelman-Sundberg M
Pharmacogenomics J; 2013 Feb; 13(1):1-11. PubMed ID: 23089672
[TBL] [Abstract][Full Text] [Related]
16. Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma.
Zhou J; Wen Q; Li SF; Zhang YF; Gao N; Tian X; Fang Y; Gao J; Cui MZ; He XP; Jia LJ; Jin H; Qiao HL
Oncotarget; 2016 Aug; 7(31):50612-50623. PubMed ID: 27203676
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.
Kirchheiner J; Seeringer A
Biochim Biophys Acta; 2007 Mar; 1770(3):489-94. PubMed ID: 17113714
[TBL] [Abstract][Full Text] [Related]
18. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.
Ingelman-Sundberg M; Sim SC; Gomez A; Rodriguez-Antona C
Pharmacol Ther; 2007 Dec; 116(3):496-526. PubMed ID: 18001838
[TBL] [Abstract][Full Text] [Related]
19. Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression.
Temesvári M; Kóbori L; Paulik J; Sárváry E; Belic A; Monostory K
J Pharmacol Exp Ther; 2012 Apr; 341(1):294-305. PubMed ID: 22262920
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of gypenosides on seven human cytochrome P450 enzymes in vitro.
He M; Jiang J; Qiu F; Liu S; Peng P; Gao C; Miao P
Food Chem Toxicol; 2013 Jul; 57():262-5. PubMed ID: 23583485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
